Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

Zoely vs Zoloft

A randomised double-blinded interventional pilot of Zoely and Zoloft to treat Premenstrual Dysphoric Disorder (ACTRN12623000496617p)

Currently recruiting

MHT vs SSRI

A randomised double-blinded interventional trial of estradiol and zoloft to treat menopausal depression (ACTRN12624000475549p)

Currently recruiting

Estradiol in CTD

A randomised placebo controlled trial of estradiol for the treatment of women with borderline personality disorder. (ACTRN12617001317381)

Currently recruiting

R3ACT-R

A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation (R3ACT Randomised (R3R)) (ACTRN12620000171910p)

Currently recruiting

BEACON-IPF

A randomised, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (NCT06097260)

Currently recruiting

FpA-AS-30094

A randomised, double-blind, multicentre, Active-controlled, parallel-group study to evaluate the efficacy and safety of fluticasone proprionate/alburterol sulfate fixed-dose combination on severe asthma exacerbations in patients with Asthma (NCT06052267)

Currently recruiting

APM002

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s Disease (ACTRN12623000843651)

Currently recruiting

APM001

A Randomised, Double-Blind, Parallel-Group,Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease (ACTRN12620000560998)

Currently recruiting

EPO_TRAUMA

A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in machnically ventilated critically ill patients following traumatic injury. (ACTRN12619001632189)

Currently recruiting

A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis [IPF]

A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis [IPF] (NCT06335303)

Currently recruiting

AIE001

A randomised, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of rozanolixizumab in adult study participants with leucine-rich glioma inactivated 1 autoimmune encephalitis (NCT04875975)

Recently completed/closed

KER-012-A201

A Randomised, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (NCT05975905)

Currently recruiting

I-MAT

A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)

Currently recruiting

SURFACE ONCOLOGY

A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (NCT05359861)

Currently recruiting

KRYSTAL-10

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (NCT04793958)

No longer recruiting

STOP-GAP

A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)

No longer recruiting

SABR-COMET 10

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)

No longer recruiting

PACIFICA

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/µL) (NCT03165734)

Currently recruiting

CLOU064J12301

A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa (NCT06799000)

Currently recruiting

ABIVAX Maintenance

A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis. (NCT05535946)

Currently recruiting
13 14 15 16 17